Search Within

Advanced Practice Providers

  1. "Principal Biostatisticians "
Formats
  1. Journal Article (6)
  2. Meeting Abstract (4)
  3. Miscellaneous (1)
Groups
  1. Epidemiology and Biostatistics (11)
  2. Principal Biostatisticians (11)
  3. Center for Hematologic Malignancies (7)
  4. Department of Medicine (7)
  5. Hematologic Malignancies, Division of (7)
  6. Lymphoma (7)

More Groups

People
  1. Alison Moskowitz (7)
  2. Ariela Noy (7)
  3. Esther Drill (7)
  4. Steven Horwitz (7)
  5. Anita Kumar (6)
  6. Helen Hancock (6)

More People

Years
  1. 2025 (1)
  2. 2024 (1)
  3. 2022 (3)
  4. 2021 (4)
  5. 2019 (2)
Publications
  1. Annals of Surgical Oncology (3)
  2. Blood (3)
  3. Journal of Clinical Oncology (2)
  4. Breast Cancer Research and Treatment (1)
  5. Hematological Oncology (1)
  6. Nature Medicine (1)
Publishers
  1. Springer (4)
  2. American Society of Hematology (3)
  3. American Society of Clinical Oncology (2)
  4. Nature Publishing Group (1)
  5. Wiley Blackwell (1)

Results (11)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Phase II trial of nivolumab plus doxorubicin, vinblastine, dacarbazine as frontline therapy in older adults with Hodgkin lymphoma
    Journal Article

    Torka, P.; Feldman, T.; Savage, K. J.; Ganesan, N.; Drill, E.; Hancock, H.; Davey, T.; Perez, L.; Capadona, C.; Subzwari, S.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Duvelisib plus romidepsin in relapsed/refractory T cell lymphomas: A phase 1b/2a trial
    Journal Article

    Horwitz, S. M.; Nirmal, A. J.; Rahman, J.; Xu, R.; Drill, E.; Galasso, N.; Ganesan, N.; Davey, T.; Hancock, H.; Perez, L.; more...
    Nature Medicine (2024)

    Fulltext@MSK | Save
  • Accuracy of the Breast Cancer Surveillance Consortium model among women with LCIS
    Journal Article

    Eroglu, I.; Sevilimedu, V.; Park, A.; King, T. A.; Pilewskie, M. L.
    Breast Cancer Research and Treatment (2022)

    Fulltext@MSK | Save
  • Comparison of outcomes for classic-type lobular carcinoma in situ managed with surgical excision after core biopsy versus observation
    Journal Article

    Matar, R.; Sevilimedu, V.; Park, A.; King, T. A.; Pilewskie, M.
    Annals of Surgical Oncology (2022)

    Fulltext@MSK | Save
  • ASO Visual Abstract: Comparison of outcomes for classic-type lobular carcinoma in situ managed with surgical excision after core biopsy versus observation
    Miscellaneous

    Matar, R.; Sevilimedu, V.; Park, A.; King, T. A.; Pilewskie, M.
    Annals of Surgical Oncology (2022)

    Fulltext@MSK | Save
  • A phase 2 biomarker-driven study of ruxolitinib demonstrates effectiveness of JAK/STAT targeting in T-cell lymphomas
    Journal Article

    Moskowitz, A. J.; Ghione, P.; Jacobsen, E.; Ruan, J.; Schatz, J. H.; Noor, S.; Myskowski, P.; Vardhana, S.; Ganesan, N.; Hancock, H.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Phase II trial of pembrolizumab plus gemcitabine, vinorelbine, and liposomal doxorubicin as second-line therapy for relapsed or refractory classical Hodgkin lymphoma
    Journal Article

    Moskowitz, A. J.; Shah, G.; Schöder, H.; Ganesan, N.; Drill, E.; Hancock, H.; Davey, T.; Perez, L.; Ryu, S.; Sohail, S.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • The combination of duvelisib and romidepsin (DR) is highly active against relapsed/refractory peripheral T‐cell lymphoma with low rates of transaminitis: Final results
    Meeting Abstract

    Horwitz, S. M.; Moskowitz, A. J.; Mehta‐Shah, N.; Jacobsen, E. D.; Khodadoust, M. S.; Ganesan, N.; Drill, E.; Hancock, H.; Davey, T.; Myskowski, P.; more...
    Hematological Oncology (2021)

    Fulltext@MSK | Save
  • Comparison of outcomes for classic-type lobular carcinoma in situ managed with surgical excision versus core biopsy alone
    Meeting Abstract

    Matar, R.; Sevilimedu, V.; Park, A.; King, T.; Pilewskie, M.
    Annals of Surgical Oncology (2021)

    Fulltext@MSK | Save
  • A pilot study of brentuximab vedotin combined with AVD chemotherapy and radiotherapy in patients with newly diagnosed early stage, unfavorable risk Hodgkin lymphoma
    Meeting Abstract

    Kumar, A.; Casulo, C.; Advani, R. H.; Budde, L. E.; Barr, P. M.; Batlevi, C. L.; Caron, P.; Constine, L. S.; Dandapani, S.; Drill, E.; more...
    Blood (2019)

    Fulltext@MSK | Save